

Table 1: Baseline Characteristics

| | Continuous Infusion (n=23) | Intermittent Bolus (n=20) | <i>p</i>-value |
|--|---------------------------------------|--------------------------------------|-----------------------|
| Male gender – n (%) | 11 (48%) | 15 (75%) | 0.069 |
| Median gestational age (weeks) – median (IQR) | 38.71 (36.00-40.00) | 37.79 (26.14-39.28) | 0.130 |
| Age at PH diagnosis (days) – median (IQR, range) | 0 (IQR 0-0, range 0-170) | 0 (IQR 0-30.5, range 0-186) | 0.230 |
| PH class – n (%) | | | 0.070* |
| PH due to lung disease/hypoxia | 9 (39%) | 14 (70%) | |
| Persistent PH of the newborn | 13 (57%) | 5 (25%) | |
| PH due to left heart disease | 1 (4%) | 1 (5%) | |
| Extracorporeal membrane oxygenation (ECMO) – n (%) | 12 (52%) | 6 (30%) | 0.140 |

PH = pulmonary hypertension.

*Results from Fisher's exact test

Table 2. Baseline Clinical Parameters

| Clinical Parameter | Continuous Infusion (n=23) Median (IQR) | Intermittent Bolus (n=20) Median (IQR) | <i>p</i>-value |
|---------------------------|--|---|-----------------------|
| MAP (mmHg) | 51 (40-61) | 53 (44-60) | 0.450 |
| SBP (mmHg) | 67 (55-78) | 76 (55-82) | 0.380 |
| DBP (mmHg) | 38 (32-55) | 44 (37-47) | 0.740 |
| SpO2 (%) | 92 (73-96) | 93 (91-96) | 0.400 |
| FiO2 (%) | 93 (55-100) | 46 (36-78) | 0.012 |
| VIS | 10 (3-20) | 4 (0-6) | 0.012 |

MAP = mean arterial pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; SpO2 = oxygen saturation; FiO2 = fraction of inspired oxygen; VIS = vasoactive infusion score.

Table 3. Change in Clinical Parameters after Sildenafil Administration

| Clinical Parameter | Continuous Infusion (n=23) Median (IQR) | Intermittent Bolus (n=20) Median (IQR) | p-Value |
|--|--|---|----------------|
| Change in Mean Arterial Pressure (mmHg) | -4 (-10 - 0) | -1 (-8 – 2) | 0.36 |
| Change in Systolic Blood Pressure (mmHg) | -6 (-14 - -1) | -1 (-8 – 6) | 0.14 |
| Change in Diastolic Blood Pressure (mmHg) | -4 (-10 – 0) | -4 (-8 – 2) | 0.54 |
| Change in Oxygen Saturation (%) | 0 (-5 – 1) | -1 (-2 – 0) | 0.79 |
| Change in FiO2 (%) | 0 (0 – 0) | 0 (0 – 0) | 0.83 |
| Change in VIS | 0 (0 – 5) | 0 (0 – 0) | 0.15 |
| Sildenafil discontinuation due to side effects – n (%) | 4 (17.4%) | 1 (5.0%) | 0.35 |

* Values reported are differences in parameters pre- and post-sildenafil administration.